Trial Outcomes & Findings for Nebivolol and the Endothelin (ET)-1 System (NCT NCT01395329)
NCT ID: NCT01395329
Last Updated: 2019-01-02
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
42 participants
Primary outcome timeframe
Systolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.
Results posted on
2019-01-02
Participant Flow
Participant milestones
| Measure |
Nebivolol
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Metoprolol
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Placebo
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|
|
Overall Study
STARTED
|
14
|
14
|
14
|
|
Overall Study
COMPLETED
|
14
|
14
|
14
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Nebivolol and the Endothelin (ET)-1 System
Baseline characteristics by cohort
| Measure |
Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
Total
n=42 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
42 Participants
n=4 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Continuous
|
57 years
STANDARD_DEVIATION 5.3 • n=5 Participants
|
55 years
STANDARD_DEVIATION 4.1 • n=7 Participants
|
56 years
STANDARD_DEVIATION 5.9 • n=5 Participants
|
56 years
STANDARD_DEVIATION 5.1 • n=4 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
16 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
26 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
14 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
42 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: Systolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
Systolic Blood Pressure
|
144 mmHg
Standard Error 6.6
|
126 mmHg
Standard Error 7.8
|
140 mmHg
Standard Error 6.1
|
125 mmHg
Standard Error 9.3
|
139 mmHg
Standard Error 4.9
|
134 mmHg
Standard Error 8.3
|
PRIMARY outcome
Timeframe: Diastolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
Diastolic Blood Pressure
|
89 mmHg
Standard Error 5.2
|
77 mmHg
Standard Error 5.3
|
90 mmHg
Standard Error 7.6
|
77 mmHg
Standard Error 4.8
|
86 mmHg
Standard Error 7.7
|
83 mmHg
Standard Error 7.3
|
PRIMARY outcome
Timeframe: Forearm blood flow was measured at 0-60 minutes before the 12 week drug or placebo intervention and 0-60 minutes after the 12 week drug or placebo intervention.Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.
Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
BQ-123 10 min
|
10.2 percent change from baseline
Standard Error 2.6
|
-1.0 percent change from baseline
Standard Error 1.7
|
10.0 percent change from baseline
Standard Error 3.7
|
11.1 percent change from baseline
Standard Error 2.8
|
13.1 percent change from baseline
Standard Error 4.6
|
15.7 percent change from baseline
Standard Error 3.0
|
|
Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
BQ-123 30 min
|
22.3 percent change from baseline
Standard Error 5.1
|
-1.1 percent change from baseline
Standard Error 3.3
|
23.0 percent change from baseline
Standard Error 4.6
|
21.1 percent change from baseline
Standard Error 4.8
|
26.8 percent change from baseline
Standard Error 5.1
|
23.3 percent change from baseline
Standard Error 4.5
|
|
Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
BQ-123 40 min
|
25.6 percent change from baseline
Standard Error 6.3
|
3.8 percent change from baseline
Standard Error 3.2
|
28.4 percent change from baseline
Standard Error 4.9
|
28.9 percent change from baseline
Standard Error 3.8
|
23.9 percent change from baseline
Standard Error 4.3
|
25.7 percent change from baseline
Standard Error 3.9
|
|
Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
BQ-123 50 min
|
25.8 percent change from baseline
Standard Error 4.6
|
6.1 percent change from baseline
Standard Error 3.6
|
31.4 percent change from baseline
Standard Error 5.9
|
27.7 percent change from baseline
Standard Error 4.8
|
29.0 percent change from baseline
Standard Error 5.6
|
26.5 percent change from baseline
Standard Error 4.5
|
|
Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
BQ-123 60 min
|
27.0 percent change from baseline
Standard Error 6.4
|
1.1 percent change from baseline
Standard Error 4.5
|
34.4 percent change from baseline
Standard Error 5.7
|
30.6 percent change from baseline
Standard Error 5.5
|
33.8 percent change from baseline
Standard Error 5.3
|
30.4 percent change from baseline
Standard Error 3.7
|
|
Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
BQ-123 20 min
|
17.4 percent change from baseline
Standard Error 3.3
|
6.0 percent change from baseline
Standard Error 3.3
|
18.0 percent change from baseline
Standard Error 4.7
|
18.7 percent change from baseline
Standard Error 3.2
|
20.4 percent change from baseline
Standard Error 3.1
|
14.7 percent change from baseline
Standard Error 3.9
|
PRIMARY outcome
Timeframe: Forearm blood flow was measured 0-120 minutes before the 12 week drug or placebo intervention and 0-120 minutes after the 12 week drug or placebo intervention.Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.
Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123 10 min
|
10.2 Percent change from baseline
Standard Error 2.6
|
-1.0 Percent change from baseline
Standard Error 1.7
|
10.0 Percent change from baseline
Standard Error 3.7
|
11.1 Percent change from baseline
Standard Error 2.8
|
13.1 Percent change from baseline
Standard Error 4.6
|
15.7 Percent change from baseline
Standard Error 3.0
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123 20 min
|
17.4 Percent change from baseline
Standard Error 3.3
|
6.0 Percent change from baseline
Standard Error 3.3
|
18.0 Percent change from baseline
Standard Error 4.7
|
18.7 Percent change from baseline
Standard Error 3.2
|
20.4 Percent change from baseline
Standard Error 3.1
|
14.7 Percent change from baseline
Standard Error 3.9
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123+BQ-788 80 min
|
41.3 Percent change from baseline
Standard Error 7.0
|
16.1 Percent change from baseline
Standard Error 8.2
|
44.7 Percent change from baseline
Standard Error 7.3
|
32.2 Percent change from baseline
Standard Error 7.3
|
42.6 Percent change from baseline
Standard Error 9.5
|
45.0 Percent change from baseline
Standard Error 7.9
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123 30 min
|
22.3 Percent change from baseline
Standard Error 5.1
|
-1.1 Percent change from baseline
Standard Error 3.3
|
23.0 Percent change from baseline
Standard Error 4.6
|
21.1 Percent change from baseline
Standard Error 4.8
|
26.8 Percent change from baseline
Standard Error 5.1
|
23.3 Percent change from baseline
Standard Error 4.5
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123 40 min
|
25.6 Percent change from baseline
Standard Error 6.3
|
3.8 Percent change from baseline
Standard Error 3.2
|
28.4 Percent change from baseline
Standard Error 4.9
|
28.9 Percent change from baseline
Standard Error 3.8
|
23.9 Percent change from baseline
Standard Error 4.3
|
25.7 Percent change from baseline
Standard Error 3.9
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123 50 min
|
25.8 Percent change from baseline
Standard Error 4.6
|
6.1 Percent change from baseline
Standard Error 3.6
|
31.4 Percent change from baseline
Standard Error 5.9
|
27.7 Percent change from baseline
Standard Error 4.8
|
29.0 Percent change from baseline
Standard Error 5.6
|
26.5 Percent change from baseline
Standard Error 4.5
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123 60 min
|
27.0 Percent change from baseline
Standard Error 6.4
|
1.1 Percent change from baseline
Standard Error 4.5
|
34.4 Percent change from baseline
Standard Error 5.7
|
30.6 Percent change from baseline
Standard Error 5.5
|
33.8 Percent change from baseline
Standard Error 5.3
|
30.4 Percent change from baseline
Standard Error 3.7
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123+BQ-788 70 min
|
44.0 Percent change from baseline
Standard Error 6.9
|
9.2 Percent change from baseline
Standard Error 3.7
|
33.2 Percent change from baseline
Standard Error 6.9
|
37.8 Percent change from baseline
Standard Error 5.7
|
37.5 Percent change from baseline
Standard Error 8.3
|
38.0 Percent change from baseline
Standard Error 7.5
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123+BQ-788 90 min
|
39.5 Percent change from baseline
Standard Error 7.1
|
21.8 Percent change from baseline
Standard Error 9.2
|
49.8 Percent change from baseline
Standard Error 9.5
|
47.4 Percent change from baseline
Standard Error 6.9
|
46.4 Percent change from baseline
Standard Error 8.9
|
47.1 Percent change from baseline
Standard Error 7.4
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123+BQ-788 100 min
|
47.4 Percent change from baseline
Standard Error 7.8
|
22.3 Percent change from baseline
Standard Error 8.5
|
47.5 Percent change from baseline
Standard Error 7.4
|
42.0 Percent change from baseline
Standard Error 7.6
|
57.1 Percent change from baseline
Standard Error 9.5
|
53.4 Percent change from baseline
Standard Error 8.5
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123+BQ-788 110 min
|
47.6 Percent change from baseline
Standard Error 8.5
|
18.9 Percent change from baseline
Standard Error 7.0
|
57.8 Percent change from baseline
Standard Error 10.4
|
48.1 Percent change from baseline
Standard Error 7.6
|
57.8 Percent change from baseline
Standard Error 7.8
|
52.8 Percent change from baseline
Standard Error 9.3
|
|
Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)
BQ-123+BQ-788 120 min
|
57.6 Percent change from baseline
Standard Error 9.0
|
20.4 Percent change from baseline
Standard Error 7.6
|
64.6 Percent change from baseline
Standard Error 9.8
|
55.4 Percent change from baseline
Standard Error 7.1
|
57.9 Percent change from baseline
Standard Error 9.5
|
49.5 Percent change from baseline
Standard Error 10.3
|
PRIMARY outcome
Timeframe: Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.FBF was measured via strain-gauge occlusion plethysmography at rest and in response to ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.
Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
FBF Response to Acetylcholine (ACh)
Baseline
|
5.2 mL/100 mL tissue/min
Standard Error 0.3
|
4.9 mL/100 mL tissue/min
Standard Error 0.4
|
5.3 mL/100 mL tissue/min
Standard Error 0.5
|
5.6 mL/100 mL tissue/min
Standard Error 0.5
|
4.8 mL/100 mL tissue/min
Standard Error 0.2
|
5.1 mL/100 mL tissue/min
Standard Error 0.3
|
|
FBF Response to Acetylcholine (ACh)
ACh 4.0
|
12.1 mL/100 mL tissue/min
Standard Error 0.8
|
13.9 mL/100 mL tissue/min
Standard Error 0.9
|
12.4 mL/100 mL tissue/min
Standard Error 1.0
|
12.0 mL/100 mL tissue/min
Standard Error 1.0
|
11.4 mL/100 mL tissue/min
Standard Error 0.6
|
13.2 mL/100 mL tissue/min
Standard Error 0.7
|
|
FBF Response to Acetylcholine (ACh)
ACh 8.0
|
12.7 mL/100 mL tissue/min
Standard Error 0.8
|
15.0 mL/100 mL tissue/min
Standard Error 0.8
|
13.1 mL/100 mL tissue/min
Standard Error 1.1
|
13.2 mL/100 mL tissue/min
Standard Error 1.1
|
12.0 mL/100 mL tissue/min
Standard Error 0.6
|
13.7 mL/100 mL tissue/min
Standard Error 0.6
|
|
FBF Response to Acetylcholine (ACh)
ACh 16.0
|
13.3 mL/100 mL tissue/min
Standard Error 0.8
|
16.4 mL/100 mL tissue/min
Standard Error 0.6
|
13.8 mL/100 mL tissue/min
Standard Error 1.1
|
14.1 mL/100 mL tissue/min
Standard Error 1.1
|
12.7 mL/100 mL tissue/min
Standard Error 0.8
|
13.9 mL/100 mL tissue/min
Standard Error 0.7
|
PRIMARY outcome
Timeframe: Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.FBF was measured via strain-gauge occlusion plethysmography at rest and in response to sodium nitroprusside (1.0, 2.0 and 4.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.
Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
FBF Response to Sodium Nitroprusside
Baseline
|
5.2 mL/100 mL tissue/min
Standard Error 0.4
|
4.7 mL/100 mL tissue/min
Standard Error 0.3
|
4.9 mL/100 mL tissue/min
Standard Error 0.3
|
5.7 mL/100 mL tissue/min
Standard Error 0.5
|
5.2 mL/100 mL tissue/min
Standard Error 0.3
|
5.2 mL/100 mL tissue/min
Standard Error 0.3
|
|
FBF Response to Sodium Nitroprusside
Sodium Nitroprusside 1.0
|
13.5 mL/100 mL tissue/min
Standard Error 1.2
|
13.7 mL/100 mL tissue/min
Standard Error 1.0
|
14.1 mL/100 mL tissue/min
Standard Error 1.3
|
14.3 mL/100 mL tissue/min
Standard Error 1.2
|
12.8 mL/100 mL tissue/min
Standard Error 0.7
|
13.7 mL/100 mL tissue/min
Standard Error 0.8
|
|
FBF Response to Sodium Nitroprusside
Sodium Nitroprusside 4.0
|
15.9 mL/100 mL tissue/min
Standard Error 1.2
|
16.4 mL/100 mL tissue/min
Standard Error 1.1
|
15.8 mL/100 mL tissue/min
Standard Error 1.3
|
16.0 mL/100 mL tissue/min
Standard Error 1.0
|
15.8 mL/100 mL tissue/min
Standard Error 0.8
|
16.1 mL/100 mL tissue/min
Standard Error 0.9
|
|
FBF Response to Sodium Nitroprusside
Sodium Nitroprusside 2.0
|
15.3 mL/100 mL tissue/min
Standard Error 1.3
|
15.2 mL/100 mL tissue/min
Standard Error 1.0
|
14.9 mL/100 mL tissue/min
Standard Error 1.3
|
15.1 mL/100 mL tissue/min
Standard Error 1.1
|
14.4 mL/100 mL tissue/min
Standard Error 0.8
|
15.3 mL/100 mL tissue/min
Standard Error 0.8
|
PRIMARY outcome
Timeframe: Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.FBF was measured via strain-gauge occlusion plethysmography at rest and in response to BQ-123+BQ-788 +ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.
Outcome measures
| Measure |
Before Nebivolol
n=14 Participants
Before randomization to Nebivolol
|
After Nebivolol
n=14 Participants
Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Metoprolol
n=14 Participants
Before randomization to Metoprolol
|
After Metoprolol
n=14 Participants
Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks
|
Before Placebo
n=14 Participants
Before randomization to placebo
|
After Placebo
n=14 Participants
Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks
|
|---|---|---|---|---|---|---|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
Baseline
|
5.0 mL/100 mL tissue/min
Standard Error 0.3
|
4.7 mL/100 mL tissue/min
Standard Error 0.3
|
5.5 mL/100 mL tissue/min
Standard Error 0.4
|
6.0 mL/100 mL tissue/min
Standard Error 0.5
|
4.9 mL/100 mL tissue/min
Standard Error 0.2
|
5.1 mL/100 mL tissue/min
Standard Error 0.3
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
ACh 4.0
|
11.7 mL/100 mL tissue/min
Standard Error 0.8
|
13.8 mL/100 mL tissue/min
Standard Error 0.9
|
13.1 mL/100 mL tissue/min
Standard Error 1.1
|
12.4 mL/100 mL tissue/min
Standard Error 1.1
|
11.7 mL/100 mL tissue/min
Standard Error 0.6
|
13.3 mL/100 mL tissue/min
Standard Error 0.7
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
ACh 8.0
|
12.3 mL/100 mL tissue/min
Standard Error 0.7
|
15.0 mL/100 mL tissue/min
Standard Error 0.7
|
13.7 mL/100 mL tissue/min
Standard Error 1.2
|
13.7 mL/100 mL tissue/min
Standard Error 1.2
|
12.3 mL/100 mL tissue/min
Standard Error 0.7
|
13.7 mL/100 mL tissue/min
Standard Error 0.7
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
Baseline+BQ123/788
|
6.4 mL/100 mL tissue/min
Standard Error 0.5
|
5.8 mL/100 mL tissue/min
Standard Error 0.7
|
6.7 mL/100 mL tissue/min
Standard Error 0.4
|
7.4 mL/100 mL tissue/min
Standard Error 0.7
|
6.1 mL/100 mL tissue/min
Standard Error 0.4
|
5.6 mL/100 mL tissue/min
Standard Error 0.4
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
ACh 4.0+BQ-123/788
|
14.6 mL/100 mL tissue/min
Standard Error 0.7
|
13.7 mL/100 mL tissue/min
Standard Error 0.9
|
16.1 mL/100 mL tissue/min
Standard Error 1.3
|
16.5 mL/100 mL tissue/min
Standard Error 1.3
|
13.5 mL/100 mL tissue/min
Standard Error 1.0
|
15.3 mL/100 mL tissue/min
Standard Error 0.9
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
ACh 8.0+BQ-123/788
|
15.3 mL/100 mL tissue/min
Standard Error 0.7
|
14.5 mL/100 mL tissue/min
Standard Error 0.8
|
17.1 mL/100 mL tissue/min
Standard Error 1.2
|
17.6 mL/100 mL tissue/min
Standard Error 1.2
|
15.1 mL/100 mL tissue/min
Standard Error 0.9
|
16.5 mL/100 mL tissue/min
Standard Error 0.9
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
ACh 16.0+BQ-123/788
|
15.9 mL/100 mL tissue/min
Standard Error 0.6
|
15.0 mL/100 mL tissue/min
Standard Error 0.7
|
17.9 mL/100 mL tissue/min
Standard Error 1.3
|
18.2 mL/100 mL tissue/min
Standard Error 1.2
|
16.2 mL/100 mL tissue/min
Standard Error 0.9
|
17.3 mL/100 mL tissue/min
Standard Error 1.0
|
|
FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)
ACh 16.0
|
12.9 mL/100 mL tissue/min
Standard Error 0.7
|
16.1 mL/100 mL tissue/min
Standard Error 0.5
|
14.5 mL/100 mL tissue/min
Standard Error 1.2
|
14.7 mL/100 mL tissue/min
Standard Error 1.2
|
13.0 mL/100 mL tissue/min
Standard Error 0.8
|
13.9 mL/100 mL tissue/min
Standard Error 0.8
|
Adverse Events
Nebivolol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Metoprolol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place